Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352578 | 1.00 | CYP19A1 (0.49) | CYP19A1CYP11B1CYP11B2TBXAS1POLB | |
| SCHEMBL2352569 | 1.00 | CYP19A1 (0.49) | CYP19A1CYP11B1CYP11B2TBXAS1POLB | |
| SCHEMBL7569566 | 1.00 | CYP19A1 (0.49) | CYP19A1CYP11B1CYP11B2TBXAS1POLB | |
| SCHEMBL2349538 | 0.94 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2TBXAS1GAA | |
| SCHEMBL2349536 | 0.94 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2TBXAS1GAA | |
| SCHEMBL2349541 | 0.94 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2TBXAS1GAA | |
| Hydrochloric Acid SCHEMBL9795383 | 0.89 | CYP19A1 (0.54) | CYP19A1CYP11B1CYP11B2TBXAS1POLB | |
| Hydrochloric Acid SCHEMBL9795376 | 0.89 | CYP19A1 (0.54) | CYP19A1CYP11B1CYP11B2TBXAS1POLB | |
| SCHEMBL2352076 | 0.88 | CYP19A1 (0.50) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL2352068 | 0.88 | CYP19A1 (0.50) | CYP19A1CYP11B1CYP11B2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | claimed |
| US-5162337-A | Administering Steroid Biosynthesis Inhibitors | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | claimed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | claimed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1898923-A1 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | Casper, Robert F. (CA) | 2008-03-19 | — | — | EP | disclosed |
| WO-2003082254-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AROMATASE INHIBITOR AND AN ESTROGEN SUITABLE FOR HORMONE REPLACEMENT THERAPY FOR A MALE | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002083241-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083240-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| US-5162337-A | Administering Steroid Biosynthesis Inhibitors | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0479570-A2 | Animal growth promotion with aromatase inhibitors | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| US-5032607-A | Enzyme inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-07-16 | — | — | US | disclosed |
| US-4866086-A | PHENYLTRIAZOLYL OLEFINIC AROMATASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP19A1 1/4885CYP11B1 20/4885CYP11B2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.